Griffin Asset Management Inc. increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 63.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,510 shares of the biopharmaceutical company’s stock after acquiring an additional 10,244 shares during the quarter. Griffin Asset Management Inc.’s holdings in Gilead Sciences were worth $2,148,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. FMR LLC boosted its position in shares of Gilead Sciences by 1.1% during the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after acquiring an additional 258,005 shares during the last quarter. Macquarie Group Ltd. boosted its position in shares of Gilead Sciences by 26.6% during the 3rd quarter. Macquarie Group Ltd. now owns 479,332 shares of the biopharmaceutical company’s stock valued at $38,836,000 after acquiring an additional 100,741 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Gilead Sciences by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after acquiring an additional 2,148,697 shares during the last quarter. Northern Trust Corp boosted its position in shares of Gilead Sciences by 0.7% during the 2nd quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after acquiring an additional 116,780 shares during the last quarter. Finally, Toronto Dominion Bank boosted its position in shares of Gilead Sciences by 19.0% during the 2nd quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock valued at $33,445,000 after acquiring an additional 75,364 shares during the last quarter. 75.84% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $78.22 on Friday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.55. The stock has a market cap of $108,106.83, a PE ratio of 22.48, a price-to-earnings-growth ratio of -1.83 and a beta of 1.22. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $89.54.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.67 by $0.11. The company had revenue of $5.95 billion for the quarter, compared to analyst estimates of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The business’s revenue for the quarter was down 18.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.70 earnings per share. sell-side analysts anticipate that Gilead Sciences, Inc. will post 6.47 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be paid a dividend of $0.57 per share. The ex-dividend date is Thursday, March 15th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a yield of 2.91%. Gilead Sciences’s dividend payout ratio is 59.77%.

Several brokerages have recently weighed in on GILD. Mizuho set a $83.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Monday. ValuEngine raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Citigroup reissued a “buy” rating and set a $105.00 price target (up previously from $103.00) on shares of Gilead Sciences in a research report on Thursday. Bank of America boosted their price target on shares of Gilead Sciences from $82.00 to $87.00 and gave the company a “neutral” rating in a research report on Wednesday. Finally, Morgan Stanley lowered their price target on shares of Gilead Sciences from $87.00 to $84.00 and set an “equal weight” rating on the stock in a research report on Wednesday. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $86.56.

In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $74.64, for a total transaction of $1,119,600.00. Following the sale, the executive vice president now directly owns 70,988 shares in the company, valued at $5,298,544.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman John C. Martin sold 50,000 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $83.56, for a total transaction of $4,178,000.00. Following the sale, the chairman now owns 3,046,766 shares in the company, valued at $254,587,766.96. The disclosure for this sale can be found here. Insiders have sold 578,333 shares of company stock worth $44,100,508 over the last quarter. Insiders own 1.30% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Griffin Asset Management Inc. Purchases 10,244 Shares of Gilead Sciences, Inc. (GILD)” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/griffin-asset-management-inc-purchases-10244-shares-of-gilead-sciences-inc-gild/1854354.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.